March 5, 2025
We uncover functional protein & metabolite biomarkers that elucidate dynamic disease biology, mechanism of action, and responder profiles to de-risk development for better outcomes.
Through diverse multi-omics services and our DynamiQ™ molecular-clinical database, Sapient generates deeper molecular data, integrates it across every omics layer, and grounds it in real-world human evidence – so your insights come with the confidence to act.
By identifying actionable biological mechanisms, we help you rapidly move from discovery to decision-making and confidently:
Validate findings and strengthen evidence to advance the right drug candidates with Sapient’s DynamiQ™ platform for:
Drug development often stalls when disease biology and drug mechanisms are insufficiently understood in humans. We make more of this biology explainable to fundamentally shift your odds of success.
The dynamic omics data Sapient generates adds the biological & disease context needed to functionally validate biomarkers and targets, ensuring the most promising proceed.
See example use cases in your research area:
Identify and prioritize novel targets through deep biological profiling.
Enable rapid proof-of-mechanism with protein- and pathway-level resolution:
Strengthen oncology trials with mechanistic insight to stratify patients.
Decipher the heterogeneity underlying abnormal metabolic states.
Leverage Sapient’s platform & DynamiQ data to confirm biomarker findings.
Enable adaptive trials with monitoring of dynamic omic markers.
Reveal novel CNS disease biology & mechanisms that may be unpredicted by established biomarkers.
Validate CNS biomarkers & targets by adding mechanistic context.
Leverage dynamic markers to read out evolving disease & treatment response.
Uncover the non-genetic factors that influence autoimmunity.
Enable deep immune phenotyping with Sapient’s DynamiQ data.
Stratify patients by disease subtype and/or likelihood of response.
Look beyond genetic sequence alone to decipher rare disease biology.
Confirm systemic pathology resulting from genetic mutations.
Leverage direct protein measures for accurate readout of therapeutic effects.
How Sapient’s next-generation FFPE Proteomics method measures >10,000 proteins in a single FFPE tumor section, delivering protein- and pathway-level resolution across 200+ oncogenic pathways.
See novel findings from a study combining cytokine profiling, discovery proteomics, and discovery metabolomics to characterize changes in inflammatory markers following weight loss intervention.
See how the NULISAqpcr AD 5-plex assay enables absolute quantitation of APOE4, BD-pTau217, Aβ42, GFAP, and NfL, allowing for integrated assessment of AD and dementia.
See how this landmark study supported by Sapient establishes causative linkages between lysosomal dysfunction and oxysterol metabolism, endothelial cell inflammation, and pulmonary arterial hypertension (PAH).
Detailing the discovery of specific small molecules that are altered in patients with sequence-verified mitochondrial disease- found to be in a biochemical pathway not yet described before in humans.
Our high throughput workflows ensure rapid turnaround of data and insights within and across all development phases.
Our high throughput workflows ensure rapid turnaround of data and insights within and across all development phases.
